Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

FDA Feedback on Viral Shedding Study Designs for Systemically Administered AAV Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

FDA Feedback on Viral Shedding Study Designs for Systemically Administered AAV Therapies

Viral Shedding Study Design for Systemic AAV Therapies

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions

    What matrices are typically required for an AAV viral shedding study?

    A: The FDA generally expects analysis of matrices where shedding is probable. For systemic administration, this includes urine, feces, saliva, and blood (serum/plasma). Depending on the vector tropism and indication, other fluids like tears or semen may be required.

    What is the standard duration for sample collection in a shedding study?

    A: Collection duration is program-specific and driven by preliminary nonclinical data. A common approach involves frequent collection in the first week post-administration, followed by weekly collection until three consecutive samples are negative for vector DNA in all subjects and matrices.

    Which bioanalytical assays are used to quantify shed vector DNA?

    A: Quantitative PCR (qPCR) and droplet digital PCR (ddPCR) are the standard GxP-validated methods. The choice depends on the required sensitivity and precision for the specific vector and matrix. Assays must be validated to detect vector DNA sequences with high specificity.

    How does shedding data inform clinical trial design and risk assessment?

    A: Shedding data establishes the route, duration, and magnitude of viral vector clearance. This information is used to define appropriate handling precautions for clinical staff and patient households, inform the duration of contraception recommendations, and build a comprehensive environmental risk assessment for the IND submission.

Executive Summary

Designing a viral shedding study for a systemically administered AAV gene therapy requires a precise alignment of bioanalytical strategy with current FDA expectations. The objective is to generate a comprehensive dataset that characterizes the route, quantity, and duration of vector shedding in relevant biological matrices. This data directly informs the environmental risk assessment and clinical safety protocols necessary for a successful Investigational New Drug (IND) application, a process we typically support within an 18-24 month timeline.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A scientist in a modern lab analyzes colorful DNA sequencing data on a tablet.

Aligning Study Design with Regulatory Expectations

A robust viral shedding study begins with a design that anticipates regulatory scrutiny. Key parameters include the selection of appropriate animal models, the justification for chosen matrices, and the definition of collection time points. The study must be powered to detect vector clearance until levels are below the quantifiable limit of a validated assay. Franklin Biolabs leverages its experience from supporting numerous IND submissions to design studies that generate clear, defensible data packages. Since 2019, programs we have supported have maintained a 100% IND success rate, a track record continued under the Franklin Biolabs brand launched in 2024.

Our >100,000 sq ft GxP-compliant facility provides the infrastructure for these complex ).

Capsid Selection and its Impact on Shedding Profiles

The choice of AAV capsid is a primary determinant of tissue tropism and, consequently, the shedding profile. Different serotypes exhibit distinct biodistribution patterns that influence which clearance pathways are most active.

  • Liver-Tropic Capsids: Vectors designed for liver-directed gene therapy, such as those based on AAV3B or AAV8, are expected to show clearance primarily through feces via the biliary route. Comparative studies have shown that engineered capsids can offer transduction efficiencies comparable to established serotypes, making them viable candidates for clinical development (PMID: 26412589).

  • Broad Tropism Capsids: Capsids like AAVrh10 may result in wider vector distribution, potentially leading to more complex shedding profiles involving multiple matrices.

Understanding the expected tropism of a given vector allows for the development of a targeted, matrix-specific bioanalytical strategy.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

Interpreting Biodistribution Data in the Context of Shedding

Viral shedding analysis does not exist in isolation; it is a component of the overall safety assessment that includes non-target tissue biodistribution. While shedding studies quantify the vector exiting the body, biodistribution studies determine where vector DNA persists internally. This combined dataset provides a complete picture of vector fate. Long-term studies have provided evidence against AAV vector-induced tumorigenesis, showing a low frequency of adverse events and no correlation with high vector DNA levels in tissues (PMID: 16043099). This context is valuable when presenting the complete safety profile to regulatory agencies.

” ]

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities